151 related articles for article (PubMed ID: 11163817)
1. Long-term remission of ovarian hyperandrogenism after short-term treatment with a gonadotropin-releasing hormone agonist.
Efstathiadou Z; Tsatsoulis A
Fertil Steril; 2001 Jan; 75(1):59-62. PubMed ID: 11163817
[TBL] [Abstract][Full Text] [Related]
2. Use of a long-acting gonadotrophin-releasing hormone analogue in a postmenopausal woman with hyperandrogenism due to a hilus cell tumour.
Picón MJ; Lara JI; Sarasa JL; Recasens JD; Clouet R; Gonzalo MA; Rovira A
Eur J Endocrinol; 2000 Jun; 142(6):619. PubMed ID: 10822225
[TBL] [Abstract][Full Text] [Related]
3. Physiological estrogen replacement may enhance the effectiveness of the gonadotropin-releasing hormone agonist in the treatment of hirsutism.
Carmina E; Janni A; Lobo RA
J Clin Endocrinol Metab; 1994 Jan; 78(1):126-30. PubMed ID: 8288696
[TBL] [Abstract][Full Text] [Related]
4. Hyperandrogenism in a postmenopausal woman: diagnostic and therapeutic challenges.
Cheng V; Doshi KB; Falcone T; Faiman C
Endocr Pract; 2011; 17(2):e21-5. PubMed ID: 21247854
[TBL] [Abstract][Full Text] [Related]
5. Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism.
Pazos F; Escobar-Morreale HF; Balsa J; Sancho JM; Varela C
Fertil Steril; 1999 Jan; 71(1):122-8. PubMed ID: 9935128
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone agonist treatment in postmenopausal women with hyperandrogenism of ovarian origin.
Vollaard ES; van Beek AP; Verburg FA; Roos A; Land JA
J Clin Endocrinol Metab; 2011 May; 96(5):1197-201. PubMed ID: 21307133
[TBL] [Abstract][Full Text] [Related]
7. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study.
Carr BR; Breslau NA; Givens C; Byrd W; Barnett-Hamm C; Marshburn PB
J Clin Endocrinol Metab; 1995 Apr; 80(4):1169-78. PubMed ID: 7714086
[TBL] [Abstract][Full Text] [Related]
8. Postmenopausal virilization in a woman with gonadotropin dependent ovarian hyperthecosis.
Manieri C; Di Bisceglie C; Fornengo R; Grosso T; Zumpano E; Calvo F; Berardengo E; Volante M; Papotti M
J Endocrinol Invest; 1998 Feb; 21(2):128-32. PubMed ID: 9585388
[TBL] [Abstract][Full Text] [Related]
9. Combination gonadotropin-releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism.
Elkind-Hirsch KE; Anania C; Mack M; Malinak R
Fertil Steril; 1995 May; 63(5):970-8. PubMed ID: 7720941
[TBL] [Abstract][Full Text] [Related]
10. Abnormalities in the serum insulin-like growth factor-1 axis in women with hyperandrogenism.
Escobar-Morreale HF; Serrano-Gotarredona J; García-Robles R; Varela C; Sancho JM
Fertil Steril; 1998 Dec; 70(6):1090-100. PubMed ID: 9848301
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
[TBL] [Abstract][Full Text] [Related]
12. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL
Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
[TBL] [Abstract][Full Text] [Related]
13. Modified dexamethasone and gonadotropin-releasing hormone agonist (Dx-GnRHa) test in the evaluation of androgen source(s) in hirsute women.
Bidzińska B; Tworowska U; Demissie M; Milewicz A
Przegl Lek; 2000; 57(7-8):393-6. PubMed ID: 11109312
[TBL] [Abstract][Full Text] [Related]
14. Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study.
Lemay A; Faure N
J Clin Endocrinol Metab; 1994 Dec; 79(6):1716-22. PubMed ID: 7989480
[TBL] [Abstract][Full Text] [Related]
15. GnRH analogue use in postmenopausal hyperandrogenism: long-term remission.
Gueorguiev M; Grossman AB
Endocrine; 2012 Apr; 41(2):342-3. PubMed ID: 22124941
[No Abstract] [Full Text] [Related]
16. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
17. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
Ren J; Sha A; Han D; Li P; Geng J; Ma C
Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
[TBL] [Abstract][Full Text] [Related]
18. Ovarian suppression with triptorelin and adrenal stimulation with adrenocorticotropin in functional hyperadrogenism: role of adrenal and ovarian cytochrome P450c17 alpha.
Escobar-Morreale H; Pazos F; Potau N; García-Robles R; Sancho JM; Varela C
Fertil Steril; 1994 Sep; 62(3):521-30. PubMed ID: 8062947
[TBL] [Abstract][Full Text] [Related]
19. Ovarian suppression reduces clinical and endocrine expression of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Carmina E; Lobo RA
Fertil Steril; 1994 Oct; 62(4):738-43. PubMed ID: 7926082
[TBL] [Abstract][Full Text] [Related]
20. Lack of an ovarian function influence on the increased adrenal androgen secretion present in women with functional ovarian hyperandrogenism.
Escobar-Morreale HF; Serrano-Gotarredona J; García-Robles R; Sancho JM; Varela C
Fertil Steril; 1997 Apr; 67(4):654-62. PubMed ID: 9093190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
